Observational studyJCO precision oncology2026

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors.

Thomas N O'Connor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.